Zoetis

Zoetis

About Zoetis

Simplify's Rating
Why Zoetis is rated
A
Rated A on Competitive Edge
Rated A on Growth Potential
Rated A on Rating Differentiation

Industries

Food & Agriculture

Healthcare

Company Size

5,001-10,000

Company Stage

IPO

Total Funding

$14.9M

Headquarters

Parsippany-Troy Hills, New Jersey

Founded

1952

Overview

Simplify Jobs

Simplify's Take

What believers are saying

  • Zoetis benefits from the growing veterinary telehealth market and increased pet ownership.
  • The rise of pet insurance boosts demand for Zoetis' advanced veterinary services.
  • Zoetis' focus on sustainable practices aligns with industry trends and consumer preferences.

What critics are saying

  • Emerging biotech firms in animal health could threaten Zoetis' market share.
  • Alternative protein sources may reduce demand for traditional animal health products.
  • Animal rights backlash against testing practices could harm Zoetis' public image.

What makes Zoetis unique

  • Zoetis leads the animal health industry with innovative products like Vetscan OptiCell.
  • The company has a strong history, originating from a Pfizer spinoff in 2013.
  • Zoetis collaborates with institutions like Colorado State University for sustainable animal production.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$14.9M

Above

Industry Average

Funded Over

1 Rounds

Grant funding comparison data is currently unavailable. We're working to provide this information soon!
Grant Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Hybrid Work Options

Company News

MarketBeat
Jan 17th, 2025
Miracle Mile Advisors LLC Makes New $272,000 Investment in Zoetis Inc. (NYSE:ZTS)

Miracle Mile Advisors LLC makes new $272,000 investment in Zoetis Inc. (NYSE:ZTS).

TipRanks
Jan 13th, 2025
Zoetis Highlights Growth at J.P. Morgan Conference

Zoetis announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, showcasing its exemplary 2024 performance and strategic growth initiatives.

Stock Titan
Jan 7th, 2025
Is Zoetis Inc. (NYSE: ZTS) Overvalued? Or Is It Worth Buying Now?

BetterInvesting Magazine has selected Zoetis (NYSE: ZTS) as its 'Stock to Study' for the March 2025 issue, suggesting the stock warrants further investigation by investors.

Grand View Research
Jan 1st, 2025
Animal Health Market Size To Reach $112.33 Billion By 2030

For instance, in January 2021, Zoetis launched the Poulvac Procerta HVT-IBD vaccine for poultry to protect against Infectious Bursal Disease (IBD).

Governance Intelligence
Dec 31st, 2024
GeneDx appoints former Zoetis general counsel as legal chief

Chen has joined GeneDx from Zoetis, where she was general counsel and corporate secretary for almost 12 years, a role she took on following the company's spinoff from Pfizer in 2013.

Recently Posted Jobs

Sign up to get curated job recommendations

Zoetis is Hiring for 0 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Zoetis's jobs every 8 hours, so check again soon! Browse all jobs →